CALIXAR provides high-quality membrane protein isolation and extraction services for (bio)drug discovery applications. This service is designed for Pharmaceutical and biotechnology businesses, as well as academic teams in the life sciences.
CALIXAR’s isolation service extracts native, wild-type, unmutated and untruncated targets so that pharmaceutical companies can produce antibodies and/or discovering primary leads through Structure-Based Drug Design (X-ray and cryo-EM) or High-Throughput Screening assays.
Unlike traditional approaches that mutate or truncate the native structure of membrane proteins, CALIXAR alters the lipidic environment of the proteins rather than modifying the protein itself.
This approach maintains the functional and structural integrities of the targets / antigens and has a positive result on the condition of the protein thus increasing the success rate of proteomics and drug discovery applications (including vaccines, small molecules screening, and antibody development).
CALIXAR provides a unique solubilization/stabilization technology for native membrane proteins. We maximize the success of every project in line with the requirements of our clients.
With CALIXAR’s patented technology, membrane proteins are extracted and stabilized at the same time while conserving their structural and functional integrity.
Our membrane proteins are purified and stabilized full length and wild-type (native) proteins.
CALIXAR’s membrane protein extraction and stabilization is performed in an eukaryotic system with the proper post-translational modifications (glycosylation, phosphorylation, acetylation…).
The CALIXAR® platform uses patented technologies only available for clients under specific agreements (license, co-development and service).
Our clients leverage CALIXAR’s proprietary technology and other best-in-class membrane protein technology not available anywhere else on the market.